-35.0%
PYPL vs MRNA
+537.9%
-572.9%
-87.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.2% | -3.6% | +0.3% | -3.0% |
| 7D | +1.7% | -9.0% | +10.8% | +2.4% |
| 30D | -9.7% | +137.2% | -146.9% | -19.8% |
| 3M | +29.2% | +194.8% | -165.6% | +11.3% |
| 6M | +13.9% | +167.2% | -153.3% | -1.2% |
| YTD | -8.1% | +375.9% | -384.0% | -25.8% |
| 1Y | -21.4% | +465.2% | -486.5% | -38.2% |
| 3Y | -11.8% | +30.4% | -42.2% | -21.8% |
| 5Y | -81.1% | -66.8% | -14.3% | -82.3% |
| All | -35.0% | +537.9% | -572.9% | -41.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling